Experiment in xengraft models of breast, colorectal, gastric, liver, lung, and prostate cancers as well as cholangiocarcinoma, endometrial carcinoma, and melanoma have confirmed that up-regulation of LINC00665 increases tumor burden, while its silencing decreases tumor weight (Table 2). Here, LINC00665 is linked to Familial prostate cancer.